- Home
- CUE vs VYNE Comparison
CUE vs VYNE Comparison
Compare CUE & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CUE | VYNE |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | United States | United States |
| Employees | N/A | 10 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6M | 20.4M |
| IPO Year | 2017 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CUE | VYNE |
|---|---|---|
| Price | $0.47 | $0.61 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 4.4M | 172.4K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.11 | 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,466,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 195.75 | N/A |
| 52 Week Low | $0.17 | $0.29 |
| 52 Week High | $1.03 | $1.98 |
Technical Indicators
Market Signals| Indicator | CUE | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 76.38 | 52.32 |
| Support Level | $0.26 | $0.56 |
| Resistance Level | $0.85 | $0.75 |
| Average True Range (ATR) | 0.06 | 0.02 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 61.27 | 56.41 |
Price Performance
Historical ComparisonAbout CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.